233 related articles for article (PubMed ID: 23534949)
21. Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma.
Kudo C; Yamakoshi H; Sato A; Ohori H; Ishioka C; Iwabuchi Y; Shibata H
Anticancer Res; 2011 Nov; 31(11):3719-26. PubMed ID: 22110192
[TBL] [Abstract][Full Text] [Related]
22. The kinase NIK as a therapeutic target in multiple myeloma.
Gardam S; Beyaert R
Expert Opin Ther Targets; 2011 Feb; 15(2):207-18. PubMed ID: 21204728
[TBL] [Abstract][Full Text] [Related]
23. Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.
Müller E; Bauer S; Stühmer T; Mottok A; Scholz CJ; Steinbrunn T; Brünnert D; Brandl A; Schraud H; Kreßmann S; Beilhack A; Rosenwald A; Bargou RC; Chatterjee M
Leukemia; 2017 Apr; 31(4):922-933. PubMed ID: 27686868
[TBL] [Abstract][Full Text] [Related]
24. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
[TBL] [Abstract][Full Text] [Related]
25. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
26. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments.
Hu J; Hu WX
Cancer Lett; 2018 Feb; 414():214-221. PubMed ID: 29174802
[TBL] [Abstract][Full Text] [Related]
27. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment.
Liu J; Hideshima T; Xing L; Wang S; Zhou W; Samur MK; Sewastianik T; Ogiya D; An G; Gao S; Yang L; Ji T; Bianchi G; Wen K; Tai YT; Munshi N; Richardson P; Carrasco R; Cang Y; Anderson KC
Sci Adv; 2021 Jun; 7(23):. PubMed ID: 34088671
[TBL] [Abstract][Full Text] [Related]
28. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
29. Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.
Anwer F; Gee KM; Iftikhar A; Baig M; Russ AD; Saeed S; Zar MA; Razzaq F; Carew J; Nawrocki S; Al-Kateb H; Cavalcante Parr NN; McBride A; Valent J; Samaras C
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):397-405. PubMed ID: 31036508
[TBL] [Abstract][Full Text] [Related]
30. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Siwak DR; Shishodia S; Aggarwal BB; Kurzrock R
Cancer; 2005 Aug; 104(4):879-90. PubMed ID: 16007726
[TBL] [Abstract][Full Text] [Related]
31. [Pomalidomide for multiple myeloma].
Fouquet G; Macro M; Decaux O; Fohrer C; Guidez S; Demarquette H; Le Grand C; Prodhomme C; Renaud L; Bories C; Herbaux C; Karlin L; Roussel M; Benboubker L; Hulin C; Arnulf B; Leleu X
Rev Med Interne; 2015 Sep; 36(9):613-8. PubMed ID: 26257103
[TBL] [Abstract][Full Text] [Related]
32. The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.
Baumann P; Müller K; Mandl-Weber S; Leban J; Doblhofer R; Ammendola A; Baumgartner R; Oduncu F; Schmidmaier R
Br J Haematol; 2009 Mar; 144(6):875-86. PubMed ID: 19170678
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications.
Chauhan D; Anderson KC
Apoptosis; 2003 Aug; 8(4):337-43. PubMed ID: 12815276
[TBL] [Abstract][Full Text] [Related]
34. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.
Balaji S; Ahmed M; Lorence E; Yan F; Nomie K; Wang M
J Hematol Oncol; 2018 Jun; 11(1):83. PubMed ID: 29907126
[TBL] [Abstract][Full Text] [Related]
35. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
36. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
37. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
38. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
Berenson JR; Ma HM; Vescio R
Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
[TBL] [Abstract][Full Text] [Related]
39. Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway.
Wang Y; Dong F; Wan W; Zhang Z; Wang J; Wang H; Ke X
Hematology; 2020 Dec; 25(1):424-432. PubMed ID: 33191863
[TBL] [Abstract][Full Text] [Related]
40. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
